Abstract

The major function of the Protocol Review and Monitoring System (PRMS) is to provide a mechanism for scientific review and research oversight of all UWCCC clinical research trials. The Cancer Center has charged this oversight responsibility to two committees, the Clinical Affairs Committee (CAC) and Clinical Trials Monitoring Committee (CTMC). The CAC performs review of all new research relative to its scientific merit and priority within the UWCCC. The relationship between the CAC and the University of Wisconsin Human Subjects Committee (HSC) remains strong and complementary. The HSC relies heavily on CAC scientific review and, in its formal policy, continues to support CAC authority to active, disapprove, or terminate UWCCC trials. The CTMC monitors the progress of all ongoing clinical trials reporting their findings to the CAC. An additional PRCS activity involves the monitoring oversight of cancer control/non-treatment trials, the review of all quality control and safety reports. These two committees report to UWCCC senior leadership of cancer control/non-treatment trials, the review of all quality control and safety reports. These two committees report to UWCCC senior leadership through the Clinical Research Committee (CRC) for all their activities.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014520-29
Application #
6495846
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1976-01-01
Project End
2006-03-31
Budget Start
Budget End
Support Year
29
Fiscal Year
2001
Total Cost
Indirect Cost

  Institution

Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715

  Publications

Liu, Bai; Jones, Monica; Kong, Lin et al. (2018) Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. Cytokine 107:105-112
Yu, Deyang; Yang, Shany E; Miller, Blake R et al. (2018) Short-term methionine deprivation improves metabolic health via sexually dimorphic, mTORC1-independent mechanisms. FASEB J 32:3471-3482
Carroll, Molly J; Fogg, Kaitlin C; Patel, Harin A et al. (2018) Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells. Cancer Res 78:3560-3573
Ehlerding, Emily B; Grodzinski, Piotr; Cai, Weibo et al. (2018) Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics. ACS Nano 12:2106-2121
Park, Linda; Schwei, R J; Xiong, P et al. (2018) Addressing Cultural Determinants of Health for Latino and Hmong Patients with Limited English Proficiency: Practical Strategies to Reduce Health Disparities. J Racial Ethn Health Disparities 5:536-544
Ehlerding, Emily B; Lan, Xiaoli; Cai, Weibo (2018) ""Albumin Hitchhiking"" with an Evans Blue Analog for Cancer Theranostics. Theranostics 8:812-814
Morris, Zachary S; Guy, Emily I; Werner, Lauryn R et al. (2018) Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites. Cancer Immunol Res 6:825-834
Yu, Bo; Goel, Shreya; Ni, Dalong et al. (2018) Reassembly of 89 Zr-Labeled Cancer Cell Membranes into Multicompartment Membrane-Derived Liposomes for PET-Trackable Tumor-Targeted Theranostics. Adv Mater 30:e1704934
England, Christopher G; Jiang, Dawei; Ehlerding, Emily B et al. (2018) 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging 45:110-120
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164

Showing the most recent 10 out of 1528 publications